Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Syria.
Press releases published on July 16, 2025
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire
·
July 16, 2025
Commack, NY, July 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Chiesi and Plug and Play Call for Innovative Solutions to Revolutionize Respiratory Care in the U.S.
GlobeNewswire
·
July 16, 2025
CARY, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Chiesi, an international biopharmaceutical company (Chiesi Group) and Plug and Play, the world’s largest Open Innovation platform, announced today the launch of Breathing Innovation: The Chiesi Challenge for …
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
GlobeNewswire
·
July 16, 2025
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on …
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
GlobeNewswire
·
July 16, 2025
- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms as compared to placebo - - Additional presentations highlight positive …
Jaya Biosciences Receives Patent Notices of Allowance in Japan, China, and Singapore for Novel Methods of Treating Neurological Diseases, including Alzheimer’s, Further Strengthening its Global Intellectual Property Portfolio
GlobeNewswire
·
July 16, 2025
SOUTH SAN FRANCISCO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Jaya Biosciences, Inc. (“JayaBio” or “the Company”), a privately held early-stage life-sciences company developing CNS-directed gene therapies for unmet needs in the neurodegenerative diseases, …
Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025
GlobeNewswire
·
July 16, 2025
TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after …
CVRx Announces Positive News on Outpatient Payment for Barostim
GlobeNewswire
·
July 16, 2025
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as …
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
GlobeNewswire
·
July 16, 2025
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of “Long-term …
Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call
GlobeNewswire
·
July 16, 2025
DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on …
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
GlobeNewswire
·
July 16, 2025
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, …
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
GlobeNewswire
·
July 16, 2025
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now includes …
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
July 16, 2025
WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …
Global POISE Study Reaches Milestone of 600 Orthopedic Implants in Pediatric Patients, Advancing Research on the Safety and Efficacy of OrthoPediatrics® Products
GlobeNewswire
·
July 16, 2025
WARSAW, Ind., July 16, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced a significant milestone in the ongoing …
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
GlobeNewswire
·
July 16, 2025
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime …
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
GlobeNewswire
·
July 16, 2025
Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – …
La nouvelle science des superhumains : le système d’IA BioSport™ libère le potentiel caché des athlètes
GlobeNewswire
·
July 16, 2025
CALGARY, Alberta et NEW YORK, 16 juill. 2025 (GLOBE NEWSWIRE) -- Dans une initiative qui marque le début d’une nouvelle ère dans le domaine de la sécurité et de la science de la performance des athlètes, The BioSport™ Health Inc, une société de technologie …
Neue Wissenschaft der Übermenschen: BioSport™ KI-System erschließt das verborgene Potenzial von Sportlern
GlobeNewswire
·
July 16, 2025
CALGARY, Alberta, und NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- In einem Schritt, der eine neue Ära in der Sicherheit und Leistungswissenschaft von Sportlern einläutet, hat The BioSport™ Health Inc, ein Unternehmen für Präzisionsgesundheitstechnologie, …
Evox Therapeutics Expands Scientific Advisory Board
GlobeNewswire
·
July 16, 2025
OXFORD, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (“Evox” or the “Company”), a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing …
علم Superhumans الجديد: نظام الذكاء الاصطناعي BioSport™ يكشف النقاب عن الإمكانات الرياضية الخفية
GlobeNewswire
·
July 16, 2025
كالجاري، ألبرتا ونيويورك, July 16, 2025 (GLOBE NEWSWIRE) -- في خطوة تشير إلى عصر جديد في علم السلامة والأداء الرياضي، كشفت شركة BioSport™ Health Inc، المتخصصة في بتقنيات دقيقة للرعاية الصحية، اليوم عن هيئة استشارية عالمية تابعة لها - مجموعة متنوعة من نخبة …
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
GlobeNewswire
·
July 16, 2025
Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy …